Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Terminated × melflufen × Clear all

Phase

Phase 3 2 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 60 Cyclophosphamide 53 Carboplatin 52 Paclitaxel 45 Nivolumab 42 Cisplatin 39 Dexamethasone 37 Gemcitabine 36 Radiotherapy 32 Capecitabine 29 Docetaxel 26 Rituximab 25 Bevacizumab 25 fludarabine 24 venetoclax 21 avelumab 21 atezolizumab 21 Cytarabine 21 Temozolomide 20 Fluorouracil 20 Trastuzumab 19 Oxaliplatin 19 Lenalidomide 19 Cetuximab 19 Bortezomib 19 Azacitidine 19 130-nm albumin-bound paclitaxel 19 fludarabine phosphate 18 Pemetrexed 18 Filgrastim 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03481556 2022-12-19

ANCHOR

Oncopeptides AB

Phase 1/2 Terminated

56 enrolled 22 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡